Close Menu

    Subscribe to Updates

    Get the latest information from JBUON.

    What's Hot

    Two Cases of Pancreatic Metastases from Renal Cell Carcinoma and Review of the Literature

    April 17, 2025

    Exploration of Matrix Metalloproteinase-9 and Interleukin-8 in Breast Cancer Patients with No Lymph Node Involvement

    March 14, 2025

    Surgical Treatment of Right Atrial Metastasis of the Malignant Melanoma: A Case Report

    March 6, 2025
    Facebook X (Twitter) Instagram
    JBUONJBUON
    • How to Submit
    • Author Guidelines
    Facebook X (Twitter) Instagram
    SUBMIT
    • Home
    • Browse Issues
      • In Press
      • Current Issue
      • Archives
    • About Journal
      • Journal Information
      • Editorial Board
      • Bibliographic Listings
      • Editorial Policy
      • Ethics and Malpractice Statement
    • For Authors
      • How To Submit
      • Submit Article
      • Downloads
    • Contact
    JBUONJBUON
    Home»Issues»Volume 26, Issue 6»Fucoidan inhibits ovarian cancer growth via the miR-20a-5p/ PKD2 axis
    Volume 26, Issue 6

    Fucoidan inhibits ovarian cancer growth via the miR-20a-5p/ PKD2 axis

    December 1, 2021Updated:April 29, 20242 Mins Read
    Share
    Facebook Twitter Email

    Ziqi Cheng, Yapei Lu, Yuan Fang
    Department of Gynecology, the First Hospital of Hangzhou Fuyang, Hangzhou, China

    Summary

    Purpose: This study aimed to investigate the influence of Fucoidan on changing ovarian cancer cell functions through the miR-20a-5p/PKD2 axis.

    Methods: Ovarian cancer cell lines SKOV3 and CAOV3 were treated with DMSO (negative control), 20 ng/ml Fucoidan, 50 ng/ml Fucoidan, 100 ng/ml Fucoidan, or 200 ng/ml Fucoidan for 24 hours, followed by fresh medium replacement and cell culture for another 48 hours. The proliferation inhibition rate was assessed using the CCK-8 assay. Proliferative and migratory rates in SKOV3 and CAOV3 cells induced with 100 ng/ml Fucoidan for 24 hours were determined by CCK-8, EdU, and Transwell assays. The relative levels of miR-20a-5p and PKD2 in Fucoidan-induced cells were detected. The regulatory effects of miR-20a-5p on phenotypes of Fucoidan-induced ovarian cancer cells were examined. The binding interaction between miR-20a-5p and PKD2 was assessed using dual-luciferase reporter assay and rescue experiments.

    Results: Fucoidan induction dose-dependently enhanced the proliferation inhibition rate in SKOV3 and CAOV3 cells and significantly inhibited proliferative and migratory functions in ovarian cancer cells. Fucoidan induction upregulated miR-20a-5p and downregulated PKD2 expression. The binding relationship between miR-20a-5p and PKD2 was confirmed. Overexpression of miR-20a-5p reduced proliferative and migratory functions in Fucoidan-induced ovarian cancer cells, which were reversed by overexpressed PKD2.

    Conclusions: Fucoidan inhibits ovarian cancer cell proliferation and migration via mediating the miR-20a-5p/PKD2 axis.

    Keywords: fucoidan, miR-20a-5p, PKD2, ovarian cancer, proliferation, migration.

    Full Text: PDF

    Original Article
    Previous ArticleLidocaine for ovarian cancer. Preclinical in vitro data
    Next Article CircMUC16 activates AKT3 pathway to promote the malignant progression of cervical cancer

    Related Articles

    Exploration of Matrix Metalloproteinase-9 and Interleukin-8 in Breast Cancer Patients with No Lymph Node Involvement

    Volume 27, 2024

    Malignant Diseases as a Reason for Interventions by Emergency Medical Teams in Barajevo 2023

    Volume 27, 2024

    MicroRNA signatures landscape in renal cell carcinoma – related epithelial to mesenchymal transition

    Volume 26, Issue 6
    Don't Miss
    Volume 27, 2024

    Two Cases of Pancreatic Metastases from Renal Cell Carcinoma and Review of the Literature

    April 17, 2025

    Dimosthenis Chrysikos1, Spiros Delis2, Charina Triantopoulou2, Evgenia Charitaki2, Nikos Kokoroskos2, Nikolaos Taprantzis1*, Amir Shihada1, Konstantinos…

    Exploration of Matrix Metalloproteinase-9 and Interleukin-8 in Breast Cancer Patients with No Lymph Node Involvement

    March 14, 2025

    Surgical Treatment of Right Atrial Metastasis of the Malignant Melanoma: A Case Report

    March 6, 2025

    Abdominal Aortic Aneurysm and Radiation Therapy

    October 28, 2024
    Our Picks

    MicroRNA signatures landscape in renal cell carcinoma – related epithelial to mesenchymal transition

    December 1, 2021

    Chromosomal instability landscape in uveal melanoma

    December 1, 2021

    Biomarkers and common oral cancers: Clinical trial studies

    December 1, 2021

    Subscribe to Updates

    About Us
    About Us

    Journal of BUON (Print ISSN: 1107-0625, Electronic ISSN: 2241-6293) is an independent Open Access Journal, published by BAKIS Productions LTD, and appears exclusively on the internet. It is covered/indexed in Current Awareness in Biological Sciences (BIO-BASE), EMBASE/Excerpta Medica.
    We're accepting new manuscripts right now.

    Email Us: editorial_office@jbuon.com
    Contact: Available soon

    Editorial Picks

    MicroRNA signatures landscape in renal cell carcinoma – related epithelial to mesenchymal transition

    December 1, 2021

    Chromosomal instability landscape in uveal melanoma

    December 1, 2021

    Biomarkers and common oral cancers: Clinical trial studies

    December 1, 2021
    Get in Touch

    Editor-in-Chief
    Athanasios E. Athanasiou,
    Department of Medical Oncology,
    Metaxa Cancer Hospital, Botassi 51, 18537, Piraeus, Greece
    Editorial Office: editorial_office@jbuon.com

    Publishing support
    EManuscript Technologies
    # 9, First Floor, Vinnse Towers
    Wheeler Road Extension, St. Thomas Town, Bangalore 560 084, INDIA
    E: journals@emanuscript.in 
    W : www.emanuscript.in

     

    • Home
    • Author Guidelines
    • Site Map
    • Contact Us
    © 2025 JBUON Powered by EManuscript.

    Type above and press Enter to search. Press Esc to cancel.